The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Export 11032 results:
[ Author(Asc)] Title Type Year
Filters: Filter is   [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Kountouras J., & Zavos C. (2010).  Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis.. Hepatol Res. 40(4), 446-7.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Triantafyllou G. Α., & Mantzoros C. S. (2016).  Activin A and follistatin in patients with nonalcoholic fatty liver disease.. Metabolism. 65(10), 1550-8.
Polyzos, S. A., Kita M., & Avramidis A. (2007).  Thyroid nodules - stepwise diagnosis and management.. Hormones (Athens). 6(2), 101-19.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2011).  The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature.. J Clin Gastroenterol. 45(1), 50-4.
Polyzos, S. A., Makras P., Efstathiadou Z., & Anastasilakis A. D. (2015).  Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.. Expert Opin Investig Drugs. 24(2), 145-57.
Polyzos, S. A., & Kountouras J. (2023).  Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?. Curr Vasc Pharmacol.
Polyzos, S. A., Kountouras J., Deretzi G., Zavos C., & Mantzoros C. S. (2012).  The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.. Curr Mol Med. 12(1), 68-82.
Polyzos, S. A., & Mantzoros C. S. (2023).  Sarcopenia: still in relative definition-penia and severe treatment-penia.. Metabolism. 155717.
Polyzos, S. A., & Kountouras J. (2020).  Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.. Ann Hepatol. 19(5), 579-580.
Polyzos, S. A., Goulis D. G., & Kountouras J. (2015).  Nonalcoholic fatty liver disease and polycystic ovary syndrome.. Ann Hepatol. 14(6), 941-3.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Polyzos, S. A., Kountouras J., Shields K., & Mantzoros C. S. (2013).  Irisin: a renaissance in metabolism?. Metabolism. 62(8), 1037-44.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2011).  The association between Helicobacter pylori infection and insulin resistance: a systematic review.. Helicobacter. 16(2), 79-88.
Polyzos, S. A., & Mantzoros C. S. (2015).  An update on the validity of irisin assays and the link between irisin and hepatic metabolism.. Metabolism. 64(9), 937-42.
Polyzos, S. A., Kang E. Seok, Tsochatzis E. A., Kechagias S., Ekstedt M., Xanthakos S., et al. (2020).  Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.. Metabolism. 113, 154413.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2012).  Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520-525.. Diabetes Care. 35(7), e53; author reply e54.
Polyzos, S. A., & Mantzoros C. S. (2022).  Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need.. Curr Med Res Opin. 38(6), 885-888.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Makras P., Perakakis N., Kountouras J., et al. (2018).  Irisin in metabolic diseases.. Endocrine. 59(2), 260-274.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.. Support Care Cancer. 17(10), 1329-30.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Geladari E. V., & Mantzoros C. S. (2014).  Irisin in patients with nonalcoholic fatty liver disease.. Metabolism. 63(2), 207-17.
Polyzos, S. A., & Kountouras J. (2019).  Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology.. J Clin Gastroenterol.
Polyzos, S. A., Kountouras J., Zafeiriadou E., Patsiaoura K., Katsiki E., Deretzi G., et al. (2011).  Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.. J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
Polyzos, S. A., & Mantzoros C. S. (2016).  Nonalcoholic fatty future disease.. Metabolism. 65(8), 1007-16.
Polyzos, S. A., Kountouras J., Romiopoulos I., & Polymerou V. (2013).  Serum visfatin in nonalcoholic fatty liver disease.. Ann Hepatol. 13(1), 150-1.
Polyzos, S. A., & Terpos E. (2018).  Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis.. Endocrine. 62(2), 487-489.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.